Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Snowflake Inc (SNOW) Price & Performance

Boston Scientific CorporationTrade
Snowflake IncTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Snowflake Inc — how do they compare? Boston Scientific Corporation trades at $50.99 (market cap $74.19B), while Snowflake Inc trades at $330.52 (market cap $116.01B). The key difference: Snowflake Inc is the larger of the two by market cap, and Snowflake Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

BSXSNOW
Market Cap
$74.19B$116.01B
Sector
HealthTechnology
52-Week High
$108.14$334.70
52-Week Low
$42.63$121.11
Enterprise Value
$86.27B$115.82B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.

Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.

Snowflake Inc

Snowflake (SNOW) trades at $334.7, up 1.27% on the day, reflecting strong momentum amid a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.39 exceeding expectations. Revenue growth remains robust, reaching $3.63 billion in 2025, though profitability challenges persist with a net income margin of -23.79%. Recent news highlights product innovations, including AI integrations and security enhancements, driving investor optimism.

Outlook is supported by Wall Street's bullish consensus, with 81% of analysts rating SNOW a buy and a price target of $302.18. However, high valuation multiples, intense competition, and ongoing losses present significant risks. The stock's proximity to its 52-week high suggests limited near-term upside without further positive catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Snowflake Inc

Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.

Read more on SNOW